Full notification file
Member State to which the notification was sent
Date of acknowledgement from the Member State Competent Authority
Title of the Project
Phase I clinical trial of intravenous administration of a conditionally
replicating adenovirus ICOVIR-5 in patients with locally advanced or metastasic malignant
Proposed period of release:
01/09/2010 to 01/12/2011
Name of the Institute(s) or Company(ies)
Institut Català d’Oncologia - IDIBELL, ;
3. Is the same GMO release planned elsewhere in the Community?
Has the same GMO been notified elsewhere by the same notifier?
GMO is a:
Identity of the GMO:
ICOVIR-5 (HAd5-DM-E2F-K-Δ24-RGD) is an oncolytic adenovirus derived from HAd5.
Information relating to the recipient or parental organisms from wich the GMO is derived
wildtype human adenovirus (HAd) - C
wildtype human adenovirus (HAd) serotype 5
European Commission administrative information
Consent given by the Member State Competent Authority: